Format

Send to

Choose Destination
Cancer. 2007 Nov 1;110(9):2007-11.

AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies.

Author information

1
Molecular Oncology, National Institute for Cancer Research, Genova, Italy.

Abstract

BACKGROUND:

Leukemias are dependent on Akt/NF-kappaB activation and angiogenesis.

METHODS:

The antiangiogenic Akt/NF-kappaB inhibitor xanthohumol (XN) has in vitro activity against acute and chronic myelogenous leukemia cell lines (AML, CML) and fresh samples from patients were investigated.

RESULTS:

Inhibition of cell proliferation is associated with induction of apoptosis and reduced VEGF secretion. Decreased cell invasion, metalloprotease production, and adhesion to endothelial cells observed in the presence of XN could prevent in vivo life-threatening complications of leukostasis and tissue infiltration.

CONCLUSIONS:

As endothelial cells and hematopoietic cells are mutually correlated in their development and growth, targeting both tumor cells and endothelial cells with agents possessing cytotoxic and antiangiogenic activities may lead to synergistic antitumor effects interrupting a reciprocal stimulatory loop between leukemia and endothelial cells.

PMID:
17823911
DOI:
10.1002/cncr.23017
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center